Definitive radiotherapy plus regional hyperthermia with or without chemotherapy for superior sulcus tumors: a 20-year, single center experience

Lung Cancer. 2011 Mar;71(3):338-43. doi: 10.1016/j.lungcan.2010.06.007. Epub 2010 Jul 8.


Purpose: To assess the efficacy and toxicity of definitive radiotherapy (RT) plus regional hyperthermia (HT) in treating superior sulcus tumors (SSTs), and to identify predictors of positive outcomes.

Methods and materials: Twenty-four patients with SSTs treated with definitive RT plus regional HT were retrospectively analyzed. The median total dose of RT was 70 Gy. All patients were treated with an 8-MHz RF-capacitive heating device. Twelve of 24 (50%) patients also underwent chemotherapy. Those with either subcutaneous fat measuring 2.5 cm or greater, or any other serious complications did not undergo this therapy.

Results: Overall survival, local control, and distant metastasis-free survival rates at 3 years were 47%, 55%, and 71%, respectively. Chemotherapy and younger age (<65 years) were significant predictors of the overall survival rate. Clinical stage (IIB) was a statistically significant prognostic indicator for local control survival rate. Toxicities were mild, with Grade 3 dermatitis seen in one patient.

Conclusions: Definitive RT plus regional HT with chemotherapy may be a promising treatment for SSTs. The results justify further evaluation with detailed treatment protocols in a large number of patients.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Combined Modality Therapy / adverse effects
  • Female
  • Humans
  • Hyperthermia, Induced* / adverse effects
  • Male
  • Middle Aged
  • Pancoast Syndrome / drug therapy
  • Pancoast Syndrome / radiotherapy
  • Pancoast Syndrome / therapy*
  • Survival Analysis
  • Treatment Outcome


  • Antineoplastic Agents